Elevated levels of urinary prostaglandin E metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients

Cancer Prevention Research

Volumn 2, Issue 11, 2009, Pages 957-965

  Kekatpure, Vikram D ^a   Boyle, Jay O ^b   Zhou, Xi Kathy ^a   Duffield Lillico, Anna J ^b   Gross, Neil D ^c   Lee, Nancy Y ^b   Subbaramaiah, Kotha ^a   Morrow, Jason D ^d   Milne, Ginger ^d   Lippman, Scott M ^e   Dannenberg, Andrew J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PROSTAGLANDIN E; 7 HYDROXY 5,11 DIOXOTETRANORPROSTANE 1,16 DIOIC ACID; 7-HYDROXY-5,11-DIOXOTETRANORPROSTANE-1,16-DIOIC ACID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN; PTGS2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CLINICAL ARTICLE; DISEASE COURSE; DRUG USE; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HIGH RISK PATIENT; HUMAN; MALE; METABOLITE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SMOKING; SQUAMOUS CELL CARCINOMA; URINE LEVEL; CANCER STAGING; CHEMISTRY; HEAD AND NECK TUMOR; METABOLISM; MIDDLE AGED; SURVIVAL RATE; URINE;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTAGLANDINS; RETROSPECTIVE STUDIES; SMOKING; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 74049117079     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0093     Document Type: Article

References (52)

1. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000;69:145-82.
2. DuBois RN, Awad J, Morrow J, Roberts LJ, Bishop PR. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-α and phorbol ester. J Clin Invest 1994;93:493-8.
3. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4:431-6.
4. Lupulescu A. Prostaglandins, their inhibitors and cancer. Prostaglandins Leukot Essent Fatty Acids 1996;54:83-94.
5. Jung TT, Berlinger NT, Juhn SK. Prostaglandins in squamous cell carcinoma of the head and neck: a preliminary study. Laryngoscope 1985;95:307-12.
6. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993; 122:518-23.
7. Sharon P, Ligumsky M, Rachmilewitz D, Zor U. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978;75: 638-40.
8. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999; 59:991-4.
9. △716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
10. Tiano HF, Loftin CD, Akunda J, et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 2002;62:3395-401.
11. Howe LR, Chang SH, Tolle KC, et al. HER2/neuinduced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res 2005;65:10113-9.
12. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409-12.
13. Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;99: 2254-9.
14. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase-2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000;164:361-70.
15. Zweifel BS, Davis TW, Ornberg RL, Masferrer JL. Direct evidence for a role of cyclooxygenase-2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res 2002;62:6706-11.
16. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
17. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.
18. Edelman MJ, Watson D, Wang X, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-Cancer and Leukemia Group B Trial 3023. J Clin Oncol 2008;26:848-55.
19. Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001;276: 18075-81.
20. Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003;278:35451-7.
21. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58:362-6.
22. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
23. Huang M, Stolina M, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998;58:1208-16.
24. Dohadwala M, Yang SC, Luo J, et al. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E2 induces transcriptional repressors ZEB1 and Snail in non-small cell lung cancer. Cancer Res 2006;66:5338-45.
25. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997;94:3336-40.
26. Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol 2002;33:708-14.
27. Moraitis D, Du B, De Lorenzo MS, et al. Levels of cyclooxygense-2 are increased in the oralmucosa of smokers: evidence for the role of epidermal growth factor and its ligands. Cancer Res 2005;65:664-70.
28. Piper PJ, Vane JR, Wyllie JH. Inactivation of prostaglandins by the lungs. Nature 1970;225:600-4.
29. Hamberg M, Samuelsson B. The structure of the major urinary metabolite of prostaglandin E2 in man. J Am Chem Soc 1969;91:2177-8.
30. Hamberg M, Samuelsson B. On the metabolism of prostaglandins E1 and E2 in man. J Biol Chem 1971;246:6713-21.
31. Ferretti A, Flanagan VP, Roman JM. Quantitative analysis of 11 α-hydroxy-9,15-dioxo-2,3,4,5,20-pentanor-19-carboxyprostanoic acid, the major urinary metabolite of E prostaglandins in man. Anal Biochem 1983;128:351-8.
32. Seyberth HW, Sweetman BJ, Frolich JC, Oates JA. Quantifications of the major urinary metabolite of the E prostaglandins by mass spectrometry: evaluation of the method's application to clinical studies. Prostaglandins 1976;11:381-97.
33. 2 synthesis in healthy humans and those with lung cancer. Anal Biochem 2004;334: 266-75.
34. 2 as a potential biomarker of advanced colorectal neoplasia. Clin Gastroenterol Hepatol 2006;4: 1358-65.
35. Duffield-Lillico AJ, Boyle JO, Zhou K, et al. Levels of prostaglandin E metabolite and leukotriene E4 are increased in the urine of smokers. Evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev Res 2009;2:322-9.
36. Gross ND, Boyle JO, Morrow JD, et al. Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers. Clin Cancer Res 2005;11:6087-93.
37. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356: 1944-56.
38. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100: 261-9.
39. Csiki I, Morrow JD, Sandler A, et al. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. Clin Cancer Res 2005;11:6634-40.
40. Gallo O, Franchi A, Magnelli L, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001;3:53-61.
41. Cohen EG, Almahmeed T, Du B, et al. Microsomal prostaglandin E synthase-1 is overexpressed in head and neck squamous cell carcinoma. Clin Cancer Res 2003;9:3425-30.
42. 2. J Biol Chem 2002;277:2614-19.
43. 2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289-93.
44. 2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 2009;136:1136-47.
45. 2 receptors as an alternative strategy to block cyclooxygenase-2- dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages. J Biol Chem 2006; 281:3321-8.
46. Sharma S, Stolina M, Yang SC, et al. Tumor cyclooxygenase-2-dependent suppression of dendritic cell function. Clin Cancer Res 2003;9: 961-68.
47. Choy H, Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J Natl Cancer Inst 2003;95:1440-52.
48. Panje WR. Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch Otolaryngol 1981;107:658-63.
49. Solomon SC, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials. Circulation 2008;117:2104-13.
50. Mutter R, L u B, Carbone DP, et al. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res 2009;15:2158-65.
51. Wirth LJ, Haddad RI, Lindeman NI, et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:6976-81.
52. Klapan I, Katic V, Culo F, Cuk V. Prognostic significance of plasma prostaglandin E concentration in patients with head and neck cancer. J Cancer Res Clin Oncol 1992;118:308-13.